An examination of data of people who received the Pfizer-BioNTech COVID-19 vaccine in Israel found males 14 to 30 years of age were the most susceptible to myocarditis after a second or third dose of the Pfizer-BioNTech COVID-19 vaccine, however, the overall risk remains relatively low. Among males ages 16 to 19 years, approximately 1 in 15,000 developed myocarditis after a booster dose of the Pfizer-BioNTech COVID-19 vaccine. All confirmed cases of myocarditis were mild and resolved after a short hospital stay (average of 3.5 days), and no hospital readmissions were reported in the following 90 days.
from Top Health News -- ScienceDaily https://ift.tt/1B2nWm8
No comments:
Post a Comment